Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Evaluation of the association of HER family members with efficacy of trastuzumab therapy in metastatic breast cancer

(2016) A. Koutras et al.   ANNALS OF ONCOLOGY

Hepatitis B virus mRNAs functionally sequester let-7a and enhance hepatocellular carcinoma

(2016) Mengmeng Deng et al.   CANCER LETTERS

Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells

(2016) Yingqiu Zhang et al.   CANCER LETTERS

Overcoming resistance to HER2 inhibitors through state-specific kinase binding

(2016) Chris J Novotny et al.   Nature Chemical Biology

Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway

(2015) Sharon T. Wilks   BREAST

Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer

(2015) Adela Madrid-Paredes et al.   BREAST CANCER RESEARCH AND TREATMENT

The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo

(2015) Florian A. Karreth et al.   CELL

A global microRNA screen identifies regulators of the ErbB receptor signaling network

(2015) Annabell Bischoff et al.   Cell Communication and Signaling

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

(2015) Otília Menyhart et al.   CURRENT CANCER DRUG TARGETS

A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity – CLEOPATRA and PENELOPE

(2015) Melissa Hodeib et al.   Future Oncology

Cell membrane gp96 facilitates HER2 dimerization and serves as a novel target in breast cancer

(2015) Xin Li et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies

(2015) Inês de Paula Costa Monteiro et al.   PHARMACOGENOMICS

Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients

(2014) Anna S. Berghoff et al.   BREAST

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer

(2014) Andrew R. Green et al.   BREAST CANCER RESEARCH AND TREATMENT

miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer

(2014) Xin Yan et al.   Molecular Cancer

HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression

(2014) An Na Seo et al.   PLoS One

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

(2013) Allan Lipton et al.   BREAST CANCER RESEARCH AND TREATMENT

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

(2013) Y H Park et al.   BRITISH JOURNAL OF CANCER

miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression

(2013) Manuela Ferracin et al.   Molecular Cancer

Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments

(2013) U. Ala et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance

(2012) Edita Aksamitiene et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation

(2012) Jun He et al.   EMBO REPORTS

HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis

(2012) Alberto Ocana et al.   JNCI-Journal of the National Cancer Institute

ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis

(2011) R. S. Cook et al.   CANCER RESEARCH

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Profiling the HER3/PI3K Pathway in Breast Tumors Using Proximity-Directed Assays Identifies Correlations between Protein Complexes and Phosphoproteins

(2011) Ali Mukherjee et al.   PLoS One

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

(2011) A. Chakrabarty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biological considerations and clinical applications of new HER2-targeted agents

(2010) Gerald M Higa et al.   Expert Review of Anticancer Therapy

Emerging paradigms of regulated microRNA processing

(2010) M. A. Newman et al.   GENES & DEVELOPMENT

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

(2010) Fumin Shi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EGFR signaling in breast cancer: Bad to the bone

(2010) John Foley et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

microRNA-205 Regulates HER3 in Human Breast Cancer

(2009) M. V. Iorio et al.   CANCER RESEARCH

Many roads to maturity: microRNA biogenesis pathways and their regulation

(2009) Julia Winter et al.   NATURE CELL BIOLOGY

FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

(2008) K. Kunii et al.   CANCER RESEARCH

MUC4 Mucin Interacts with and Stabilizes the HER2 Oncoprotein in Human Pancreatic Cancer Cells

(2008) P. Chaturvedi et al.   CANCER RESEARCH